常見例句The clinical and radiologic impact of natalizumab (Tysabri) as therapy for multiple sclerosis (MS) is assessed. 評估那他珠單抗治療多發(fā)性硬化的臨床和影像學損害。Keywords Natalizumab;reintroduction;risk management;RiskMap;TOUCH;FDA; 那他珠單抗;重返市場;藥品風險管理;風險管理計劃;TOUCH;FDA;Keywords multiple sclerosis;drug therapy;autoimmune diseases;integrin;natalizumab; 多發(fā)性硬化;藥物療法;自身免疫疾病;整合素;那他珠單抗; 返回 natalizumab